Biomea Fusion, Inc. Logo

Biomea Fusion, Inc.

Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.

BMEA | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1599 INDUSTRIAL ROAD, 94070 SAN CARLOS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral covalent small molecules for the treatment of metabolic diseases and genetically defined cancers. The company's primary focus is on its metabolic franchise, advancing potential disease-modifying therapies for diabetes and obesity. Its lead clinical candidates include icovamenib (BMF-219), a covalent menin inhibitor being investigated for its potential to regenerate insulin-producing beta cells in patients with Type 1 and Type 2 diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist. The company's oncology pipeline features BMF-500, a covalent FLT3 inhibitor for acute leukemia. Biomea leverages its proprietary FUSION™ System to design its drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biomea Fusion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biomea Fusion, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biomea Fusion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America ANAB
Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.
Türkiye ANGEN
ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America ANNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.